All Stories

  1. RNA-sequencing reveals that STRN, ZNF484 and WNK1 add to the value of mitochondrial MT-COI and COX10 as markers of unstable coronary artery disease
  2. Single-cell transcriptomics–based MacSpectrum reveals macrophage activation signatures in diseases
  3. Circular RNAs as Potential Theranostics in the Cardiovascular System
  4. Peer review: (r)evolution needed
  5. Low Cytochrome Oxidase 1 Links Mitochondrial Dysfunction to Atherosclerosis in Mice and Pigs
  6. Extracellular Vesicles in Cardiovascular Theranostics
  7. Functional Role of Cardiovascular Exosomes in Myocardial Injury and Atherosclerosis
  8. Low MT‐CO1 in Monocytes and Microvesicles Is Associated With Outcome in Patients With Coronary Artery Disease
  9. A Comparative Metabolomics Approach Reveals Early Biomarkers for Metabolic Response to Acute Myocardial Infarction
  10. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review
  11. Exosomes
  12. Low cytochrome oxidase 4I1 links mitochondrial dysfunction to obesity and type 2 diabetes in humans and mice
  13. Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: A transcriptomic and metabolomic study
  14. Welcome to Cardiovascular Research in 2015
  15. Biomechanical factors in atherosclerosis: mechanisms and clinical implications
  16. Rosiglitazone and Fenofibrate Exacerbate Liver Steatosis in a Mouse Model of Obesity and Hyperlipidemia. A Transcriptomic and Metabolomic Study
  17. Bedside to bench: a look at experimental research with a clinical trial checklist
  18. MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
  19. Examining the association between salivary cortisol levels and subclinical measures of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis
  20. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease
  21. Biomechanical factors and macrophages in plaque stability
  22. PPAR Agonist-Induced Reduction of Mcp1 in Atherosclerotic Plaques of Obese, Insulin-Resistant Mice Depends on Adiponectin-Induced Irak3 Expression
  23. Hematopoietic stem/progenitor cell and HDL
  24. Decreased miR-181a Expression in Monocytes of Obese Patients Is Associated with the Occurrence of Metabolic Syndrome and Coronary Artery Disease
  25. CD36 Inhibitors Reduce Postprandial Hypertriglyceridemia and Protect against Diabetic Dyslipidemia and Atherosclerosis
  26. Decrease of miR-146b-5p in Monocytes during Obesity Is Associated with Loss of the Anti-Inflammatory but Not Insulin Signaling Action of Adiponectin
  27. Mitochondrial Reactive Oxygen Species and Risk of Atherosclerosis
  28. Interleukin-1 Receptor-Associated Kinase-3 Is a Key Inhibitor of Inflammation in Obesity and Metabolic Syndrome
  29. Stress in Obesity and Associated Metabolic and Cardiovascular Disorders
  30. Dietary antioxidants and forced expiratory volume in 1 s decline: the Health, Aging and Body Composition study
  31. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis
  32. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis
  33. Differential Associations of Weight Dynamics With Coronary Artery Calcium Versus Common Carotid Artery Intima-Media Thickness
  34. Statins for Calcific Aortic Valve Stenosis: Into Oblivion After SALTIRE and SEAS? An Extensive Review from Bench to Bedside
  35. Telomere length and its associations with oxidized-LDL carotid artery distensibility and smoking
  36. Stevioside inhibits atherosclerosis by improving insulin signaling and antioxidant defense in obese insulin-resistant mice
  37. Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs
  38. The vicious circle between oxidative stress and inflammation in atherosclerosis
  39. Food-restriction in obese dyslipidaemic diabetic mice partially restores basal contractility but not contractile reserve
  40. Obesity-Asthma Association
  41. Oxidative Stress and Insulin Resistance: The Coronary Artery Risk Development in Young Adults study
  42. Relationship of lipoprotein-associated phospholipase A2and oxidized low density lipoprotein in carotid atherosclerosis
  43. Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age
  44. Oxidized LDL and the metabolic syndrome
  45. Thrombospondin-1 Deficiency Accelerates Atherosclerotic Plaque Maturation in ApoE −/− Mice
  46. Angio-Associated Migratory Cell Protein and Smooth Muscle Cell Migration in Development of Restenosis and Atherosclerosis⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily...
  47. Association Between Circulating Oxidized Low-Density Lipoprotein and Incidence of the Metabolic Syndrome
  48. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis
  49. Rosuvastatin increases vascular endothelial PPARγ expression and corrects blood pressure variability in obese dyslipidaemic mice
  50. Defective Leptin/Leptin Receptor Signaling Improves Regulatory T Cell Immune Response and Protects Mice From Atherosclerosis
  51. Oxidized low-density lipoprotein-induced expression of ABCA1 in blood monocytes precedes coronary atherosclerosis and is associated with plaque complexity in hypercholesterolemic pigs
  52. Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia
  53. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: Relation to liver, muscle and regional body fat content
  54. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: The Multi-Ethnic Study of Atherosclerosis (MESA)
  55. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness
  56. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice
  57. The complex link between oxidised low-density lipoprotein and unstable angina
  58. Gelatinolytic Activity in Atherosclerotic Plaques Is Highly Localized and Is Associated With Both Macrophages and Smooth Muscle Cells In Vivo
  59. The Importance of Catch-up Growth after Early Malnutrition for the Programming of Obesity in Male Rat*
  60. Oxidized Low-Density Lipoprotein Correlates Positively With Toll-Like Receptor 2 and Interferon Regulatory Factor-1 and Inversely With Superoxide Dismutase-1 Expression
  61. Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome
  62. Obesity, the metabolic syndrome, and oxidized LDL
  63. Oxidized LDL and the Metabolic Syndrome
  64. Metabolic Syndrome and the Risk of Cardiovascular Disease in Older Adults
  65. CREB activation induced by mitochondrial dysfunction triggers triglyceride accumulation in 3T3-L1 preadipocytes
  66. Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Circulating Oxidized LDL
  67. Peroxisome Proliferator-Activated Receptor-α,γ-Agonist Improves Insulin Sensitivity and Prevents Loss of Left Ventricular Function in Obese Dyslipidemic Mice
  68. Application of NIRS in Mice: A Study Comparing the Oxygenation of Cerebral Blood and Main Tissue Oxygenation of Mice and Rat
  69. Lipoprotein Peroxidation and Mobility Limitation
  70. Obesity, Regional Body Fat Distribution, and the Metabolic Syndrome in Older Men and Women
  71. Weight Loss–Associated Induction of Peroxisome Proliferator–Activated Receptor-α and Peroxisome Proliferator–Activated Receptor-γ Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice
  72. Oxidized LDL and coronary heart disease
  73. Molecular and Functional Characterization of Ovine Cardiac Valve-Derived Interstitial Cells in Primary Isolates and Cultures
  74. Gene Therapy Approaches for Cardiovascular Diseases
  75. The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort
  76. α-Helix Formation Is Required for High Affinity Binding of Human Apolipoprotein A-I to Lipids
  77. Association of High Coronary Heart Disease Risk Status With Circulating Oxidized LDL in the Well-Functioning Elderly
  78. Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI
  79. Domain Structure and Lipid Interaction in Human Apolipoproteins A-I and E, a General Model
  80. Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice
  81. Chlamydia pneumoniae induces neointima formation in coronary arteries of normal pigs
  82. Increased Levels of Low-Density Lipoprotein Oxidation in Patients with Familial Hypercholesterolemia and in End-Stage Renal Disease Patients on Hemodialysis
  83. Effects of Homocysteine on the Cellular Responses of Murine Endothelial Cells Culturedin Vitro
  84. Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs
  85. Hypercholesterolemia in Minipigs Impairs Left Ventricular Response to Stress
  86. Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty
  87. Effects of Enrichment of Fibroblasts with Unesterified Cholesterol on the Efflux of Cellular Lipids to Apolipoprotein A-I
  88. Antineutrophil cytoplasmatic antibodies in patients with premature atherosclerosis: prevalence and association with risk factors
  89. Identification of the phospholipase A2 isoforms that contribute to arachidonic acid release in hypoxic endothelial cells: limits of phospholipase A2 inhibitors
  90. Arg123-Tyr166 Domain of Human ApoA-I Is Critical for HDL-Mediated Inhibition of Macrophage Homing and Early Atherosclerosis in Mice
  91. Oxidized LDL and HDL: antagonists in atherothrombosis
  92. S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells
  93. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 11/2 years
  94. Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor–Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E–Deficient Mice
  95. Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease
  96. Smooth Muscle Cells Influence Monocyte Response to LDL as well as Their Adhesion and Transmigration in a Coculture Model of the Arterial Wall
  97. Restenosis and gene therapy
  98. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice
  99. Effect of Overexpression of Human Apo A-I in C57BL/6 and C57BL/6 Apo E–Deficient Mice on 2 Lipoprotein-Associated Enzymes, Platelet-Activating Factor Acetylhydrolase and Paraoxonase
  100. Oxidized Low Density Lipoprotein Is a Prognostic Marker of Transplant-Associated Coronary Artery Disease
  101. The Arg123-Tyr166 Central Domain of Human ApoAI Is Critical for Lecithin:Cholesterol Acyltransferase–Induced Hyperalphalipoproteinemia and HDL Remodeling in Transgenic Mice
  102. Sustained Expression of Human Apolipoprotein A-I after Adenoviral Gene Transfer in C57BL/6 Mice: Role of Apolipoprotein A-I Promoter, Apolipoprotein A-I Introns, and Human Apolipoprotein E Enhancer
  103. Endothelial Dysfunction, Oxidation of Low‐Density Lipoprotein, and Cardiovascular Disease
  104. Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes
  105. Role of oxidatively modified low density lipoproteins and anti-oxidants in atherothrombosis
  106. Apolipoprotein-mediated Plasma Membrane Microsolubilization
  107. Oxidized LDL and Malondialdehyde-Modified LDL in Patients With Acute Coronary Syndromes and Stable Coronary Artery Disease
  108. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
  109. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis
  110. LDL Hypercholesterolemia Is Associated With Accumulation of Oxidized LDL, Atherosclerotic Plaque Growth, and Compensatory Vessel Enlargement in Coronary Arteries of Miniature Pigs
  111. Oxidized Low Density Lipoproteins in Patients With Transplant-Associated Coronary Artery Disease
  112. Effects of Adenovirus-Mediated Human Apo A-I Gene Transfer on Neointima Formation After Endothelial Denudation in Apo E–Deficient Mice
  113. Prevention of Fatty Streak Formation of 17β-Estradiol Is Not Mediated by the Production of Nitric Oxide in Apolipoprotein E– Deficient Mice
  114. β-VLDL Hypercholesterolemia Relative to LDL Hypercholesterolemia Is Associated With Higher Levels of Oxidized Lipoproteins and a More Rapid Progression of Coronary Atherosclerosis in Rabbits
  115. Thrombosis and atherosclerosis
  116. Role of the Arg123–Tyr166Paired Helix of Apolipoprotein A-I in Lecithin:Cholesterol Acyltransferase Activation
  117. 2 The oxidation hypothesis of atherosclerosis
  118. Role of the Carboxy-Terminal Domain of Human Apolipoprotein AI in High-Density-Lipoprotein Metabolism. A Study Based on Deletion and Substitution Variants in Transgenic Mice
  119. Effects of Deletion of the Carboxyl-terminal Domain of ApoA-I or of Its Substitution with Helices of ApoA-II onin Vitroandin VivoLipoprotein Association
  120. Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants
  121. Lipid Lowering and Enhancement of Fibrinolysis With Niacin
  122. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
  123. Oxidized lipoproteins in atherosclerosis and thrombosis
  124. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
  125. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
  126. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase
  127. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
  128. Experimental Pulmonary Embolus in the Rat
  129. Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies
  130. A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis